Patents by Inventor David Kenneth Dean

David Kenneth Dean has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20120172366
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein A is hydrogen, C1-4alkyl, C3-6cycloalkyl, C1-3alkoxy, C1-3alkoxy C1-4alkyl, C1-2fluoroalkyl, halogen, NR6R7, optionally substituted heteroaryl, or optionally substituted phenyl, and R1, R2, R3, R4, R5, R6 and R7 are as defined in the description. The compounds or salts are thought to modulate P2X7 receptor function and to be capable of antagonizing the effects of ATP at the P2X7 receptor. The invention also provides the use of the compound or salt in the treatment or prophylaxis of, for example, inflammatory pain, neuropathic pain, visceral pain, rheumatoid arthritis or osteoarthritis or neurodegenerative disorders.
    Type: Application
    Filed: April 28, 2010
    Publication date: July 5, 2012
    Inventors: David Kenneth Dean, Jorge Munoz-Muriedas, Mairi Sime, Jon Graham Anthony Steadman, Rachel Elizabeth Anne Thewlis, Giancarlo Trani, Ian David Wall, Daryl Simon Walter
  • Patent number: 8207331
    Abstract: The present invention relates to novel benzazepine derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.
    Type: Grant
    Filed: February 17, 2010
    Date of Patent: June 26, 2012
    Assignee: Glaxo Group Limited
    Inventors: Mark James Bamford, David Kenneth Dean, Sanjeet Singh Sehmi, David Matthew Wilson, Jason Witherington
  • Publication number: 20120157436
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein A is hydrogen, C1-4alkyl, C3-6cycloalkyl, C1-3alkoxy, C1-3alkoxy C1-4alkyl, C1-2-fluoroalkyl, halogen, NR6R7, optionally substituted heteroaryl, or optionally substituted phenyl, and R1, R2, R3, R4, R5, R6 and R7 are as defined in the description. The compounds or salts are thought to modulate P2X7 receptor function and to be capable of antagonizing the effects of ATP at the P2X7 receptor. The invention also provides the use of the compound or salt in the treatment or prophylaxis of, for example, inflammatory pain, neuropathic pain, visceral pain, rheumatoid arthritis, osteoarthritis or neurodegenerative disorders.
    Type: Application
    Filed: April 28, 2010
    Publication date: June 21, 2012
    Inventors: David Kenneth Dean, Jorge Munoz-Muriedas, Mairi Sime, Jon Graham Anthony Steadman, Rachel Elizabeth Anne Thewlis, Giancarlo Trani, Daryl Simon Walter
  • Patent number: 7932282
    Abstract: The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof: The compounds or salts modulate P2X7 receptor function and are capable of antagonizing the effects of ATP at the P2X7 receptor (P2X7 receptor antagonists). The invention also provides the use of such compounds or salts, or pharmaceutical compositions thereof, in the treatment or prevention of disorders/diseases mediated by the P2X7 receptor, for example pain, inflammation or a neurodegenerative disease, in particular pain such as inflammatory pain, neuropathic pain or visceral pain.
    Type: Grant
    Filed: April 2, 2008
    Date of Patent: April 26, 2011
    Assignee: Glaxo Group Limited
    Inventors: Paul John Beswick, David Kenneth Dean, Robert James Gleave, Andrew Peter Moses, Daryl Simon Walter
  • Publication number: 20100311749
    Abstract: The invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein: A is C1-6alkyl, C3-6cycloalkyl, —CH2—R6, —CHMe-R7, —CMe2-R7, or optionally substituted aryl; wherein, when A is optionally substituted aryl, said aryl group is optionally substituted with 1 to 3 substituents, which may be the same or different, selected from the group consisting of halogen, C1-6alkyl, —CF3, C1-4alkoxy, C1fluoroalkoxy, cyano, NR8R9, and pyridyl wherein the pyridyl is optionally substituted by one methyl; R1 is chlorine, fluorine, —CF3, cyano or C1-6alkyl; R2, R3 and R5 independently are hydrogen, fluorine, chlorine, —CF3, cyano or C1-6alkyl, such that at least one of R2, R3 and R5 is other than hydrogen; R4 is hydrogen. These compounds and salts are thought to be P2X7 receptor antagonists. The invention also provides for the treatment of pain, inflammation, rheumatoid arthritis, osteoarthritis, or a neurodegenerative disease.
    Type: Application
    Filed: October 24, 2008
    Publication date: December 9, 2010
    Inventors: Laura Jane Chambers, Katharine Laura Collis, David Kenneth Dean, Jorge Munoz-Muriedas, Jon Graham Anthony Steadman, Daryl Simon Walter
  • Patent number: 7799773
    Abstract: The present invention relates to novel benzazepine derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.
    Type: Grant
    Filed: December 19, 2008
    Date of Patent: September 21, 2010
    Assignee: Glaxo Group Limited
    Inventors: Mark James Bamford, David Kenneth Dean, Sanjeet Singh Sehmi, David Matthew Wilson, Jason Witherington
  • Publication number: 20100179168
    Abstract: The present invention therefore provides compounds of formula (I) or pharmaceutically acceptable salts thereof: (I) processes for their preparation, pharmaceutical compositions containing the same and to their use in the treatment of gastrointestinal and other disorders.
    Type: Application
    Filed: April 13, 2007
    Publication date: July 15, 2010
    Inventors: Emma Louise Blaney, David Kenneth Dean, Alessandra Gaiba, Nigel Paul King, Jason Witherington
  • Publication number: 20100145040
    Abstract: The present invention relates to novel benzazepine derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.
    Type: Application
    Filed: February 17, 2010
    Publication date: June 10, 2010
    Inventors: Mark James Bamford, David Kenneth Dean, Sanjeet Singh Sehmi, David Matthew Wilson, Jason Witherington
  • Publication number: 20100075968
    Abstract: The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof: The compounds or salts modulate P2X7 receptor function and are capable of antagonizing the effects of ATP at the P2X7 receptor (P2X7 receptor antagonists). The invention also provides the use of such compounds or salts, or pharmaceutical compositions thereof, in the treatment or prevention of disorders/diseases mediated by the P2X7 receptor, for example pain, inflammation or a neurodegenerative disease, in particular pain such as inflammatory pain, neuropathic pain or visceral pain.
    Type: Application
    Filed: April 2, 2008
    Publication date: March 25, 2010
    Inventors: Paul John Beswick, David Kenneth Dean, Robert James Gleave, Andrew Peter Moses, Daryl Simon Walter
  • Publication number: 20100056595
    Abstract: The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein R1 represents C1-6 alkyl or C3-6 cycloalkyl, either of which is optionally substituted with 1, 2 or 3 halogen atoms; and R2 represents hydrogen, halogen, C1-6 alkyl or C3-6 cycloalkyl; and either of said C1-6 alkyl or C3-6 cycloalkyl is optionally substituted with 1, 2 or 3 halogen atoms. The pyrazole compounds of formula (I) or salts thereof modulate P2X7 receptor function and are capable of antagonizing the effects of ATP at the P2X7 receptor (P2X7 receptor antagonists). The invention also relates to the use of such compounds or salts, or pharmaceutical compositions thereof, in the treatment or prevention of disorders/diseases mediated by the P2X7 receptor, for example pain, inflammation or a neurodegenerative disease.
    Type: Application
    Filed: April 10, 2008
    Publication date: March 4, 2010
    Applicant: Glaxo Group Limited
    Inventors: Paul John Beswick, David Kenneth Dean, Daryl Simon Walter
  • Publication number: 20090149524
    Abstract: The present invention relates to novel pyrazole derivatives of formula (I) which bind to the P2X7 receptor and are capable of interfering with the effects of ATP at the P2X7 receptor: and the use of such compounds or pharmaceutical compositions thereof in the treatment of disorders mediated by the P2X7 receptor, for example pain, inflammation and neurodegeneration.
    Type: Application
    Filed: June 5, 2007
    Publication date: June 11, 2009
    Inventors: Paul John Beswick, Laura J. Chambers, David John Davies, David Kenneth Dean, Emmanuel Hubert Demont, Susan Roomans, Daryl Simon Walter
  • Publication number: 20090105226
    Abstract: The present invention relates to novel benzazepine derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.
    Type: Application
    Filed: December 19, 2008
    Publication date: April 23, 2009
    Inventors: Mark James BAMFORD, David Kenneth Dean, Sanjeet Singh Sehmi, David Matthew Wilson, Jason Witherington
  • Patent number: 7452906
    Abstract: Compounds and their use as pharmaceuticals particularly as Raf kinase inhibitors for the treatment of neurotraumatic diseases, cancer, chronic neurodegeneration, pain, migraine and cardiac hypertrophy.
    Type: Grant
    Filed: September 5, 2002
    Date of Patent: November 18, 2008
    Assignee: SmithKline Beecham P.L.C.
    Inventors: Mark James Bamford, David Kenneth Dean, Antoinette Naylor, Andrew Kenneth Takle, David Matthew Wilson
  • Patent number: 7446106
    Abstract: Compounds and their use as pharmaceuticals particularly as Raf kinase inhibitors for the treatment of neurotraumatic diseases, cancer, chronic neurodegeneration, pain, migraine and cardiac hypertrophy.
    Type: Grant
    Filed: September 5, 2002
    Date of Patent: November 4, 2008
    Assignee: SmithKline Beecham plc
    Inventors: David Kenneth Dean, Andrew Kenneth Takle, David Matthew Wilson
  • Patent number: 7381728
    Abstract: The invention provides compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein Ra, Rb, Rc, Rd, Re, Rf and Y are as defined in the specification. The compounds are partial or full agonists at the growth hormone secretagogue (GHS) receptors. Pharmaceutical compositions comprising the compounds methods of preparing the compounds, uses of the compounds and methods involving the compounds are also provided.
    Type: Grant
    Filed: July 26, 2005
    Date of Patent: June 3, 2008
    Assignee: Glaxo Group Limited
    Inventors: David Kenneth Dean, Alessandra Gaiba, Nigel Paul King, Andrew Kenneth Takle, Jason Witherington
  • Patent number: 7375105
    Abstract: Compounds and their use as pharmaceuticals particularly as Raf kinase inhibitors for the treatment of neurotraumatic diseases, cancer, chronic neurodegeneration, pain, migraine and cardiac hypertrophy. Wherein X is O, CH2 CO, S or NH, or the moiety X—R1 is hydrogen; Y1 and Y2 independently represent CH or N; Ar is a mono- or fused bicyclic aromatic or heteroaromatic group which may be optionally substituted; one of X1 and X2 is selected from O, S or NR11 and the other is CH, wherein R11 is hydrogen, C1-6alkyl, aryl or arylC1-6alkyl.
    Type: Grant
    Filed: September 5, 2002
    Date of Patent: May 20, 2008
    Assignee: SmithKline Beecham p.l.c.
    Inventors: David Kenneth Dean, Andrew Kenneth Takle, David Matthew Wilson
  • Patent number: 7297693
    Abstract: Compounds and their use as pharmaceuticals particularly as Raf kinase inhibitors for the treatment of neurotraumatic diseases, cancer, chronic neurodegeneration, pain, migraine and cardiac hypertrophy.
    Type: Grant
    Filed: September 5, 2002
    Date of Patent: November 20, 2007
    Assignee: SmithKline Beecham P.L.C.
    Inventors: Mark James Bamford, David Kenneth Dean, Antoinette Naylor, Andrew Kenneth Takle, David Matthew Wilson
  • Patent number: 7297694
    Abstract: Compounds and their use as pharmaceuticals particularly as Raf kinase inhibitors for the treatment of neurotraumatic diseases, cancer, chronic neurodegeneration, pain, migraine and cardiac hypertrophy.
    Type: Grant
    Filed: September 5, 2002
    Date of Patent: November 20, 2007
    Assignee: SmithKline Beechum P.L.C.
    Inventors: David Kenneth Dean, Antoinette Naylor, Andrew Kenneth Takle, David Matthew Wilson
  • Patent number: 7282500
    Abstract: The present invention relates to compounds of formula (I): or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, use as Raf Kinase Inhibitors and treatment methods for neurotraumatic diseases and cancer.
    Type: Grant
    Filed: May 20, 2002
    Date of Patent: October 16, 2007
    Assignee: SmithKline Beecham P.L.C.
    Inventors: David Kenneth Dean, Andrew Kenneth Takle, David Matthew Wilson
  • Patent number: 7199137
    Abstract: Novel compounds (I) and their use as pharmaceuticals particularly as Raf kinase inhibitors for the treatment of neurotraumatic diseases, cancer, chronic neurodegeneration, pain, migraine and cardiac hypertrophy wherein Ar is a group of formula a) or b).
    Type: Grant
    Filed: September 19, 2001
    Date of Patent: April 3, 2007
    Assignee: SmithKline Beecham plc
    Inventors: David Kenneth Dean, Andrew Kenneth Takle, David Matthew Wilson